Abstract:Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of clinically aggressive diseases associated with poor outcome. Despite progress in the last several years, resulting in a deeper understanding of the natural history and biology of PTCL based on molecular profiling and next-generation sequencing, there is a need for improvement in efficacy of chemotherapeutic regimens for newly diagnosed patients. Treatment in the front-line setting is most often cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like regimens, which are associated with a high failure rate and frequent relapses. Trials evaluating intensive chemotherapy have resulted in variable success in prolonging event-free survival, but overall survival has remained unchanged. Furthermore, this strategy is limited to patients who are in complete remission after initial anthracycline-based chemotherapy. Many patients are ineligible for hematopoietic stem cell transplantation because of age or failure to achieve remission. For relapsed disease, advances have been made in the therapeutic arsenal for PTCL. New drugs investigated in phase II studies have achieved response rates between 10% and 30%. However, to date the identification of new therapies has been largely empiric, and long-term remissions are the exception to the rule. Current patient outcomes suggest the need for the identification and development of active and biologically rational therapies to improve disease management and to extend the duration of response with iterative biomarker evaluation. This review covers the management of PTCL and focuses on new agents and therapeutic combinations, based on a better understanding of biology and pathogenesis of the disease. Implications for practice: Recent progress in understanding of the biology and pathogenesis of peripheral T-cell lymphoma has led to the emergence of new drugs. Unfortunately, this has not been met with similar advances in outcome improvement. Anthracycline-containing regimens, mostly cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), are considered the standard of care, although the best first-line approach remains to be defined. In the relapsed and refractory settings, several new agents achieved response rates between 10% and 30%, although these drugs do not significantly affect survival rates. Therapeutic options based on better molecular characterization of various histological types and combinations with the CHOP regimen or synergic combinations of new drugs may lead to better outcomes.

Precise Diagnosis and Targeted Therapy of Nodal T-follicular Helper Cell Lymphoma (T-FHCL)

Research Progress in Treatment of Peripheral T-cell Lymphoma

Current and upcoming treatment approaches to common subtypes of PTCL (PTCL NOS, ALCL, TFHs)

Frontline Management of Nodal Peripheral T-Cell Lymphomas

Clinicopathologic Analysis of Nodal T-follicular Helper Cell Lymphomas, a Multicenter Retrospective Study from China

Tislelizumab For The Treatment Of Classical Hodgkin'S Lymphoma

Biomarker-driven management strategies for peripheral T cell lymphoma

Past, present and future therapeutic approaches in nodal peripheral T-cell lymphomas

Novel clinical risk stratification and treatment strategies in relapsed/refractory peripheral T-cell lymphoma

SOHO State-of-the-Art Updates and Next Questions: Treatment for Newly Diagnosed Peripheral T-Cell Lymphomas

How I treat the peripheral T-cell lymphomas

Expression of follicular helper T cell markers in nodal peripheral T cell lymphomas: a tissue microarray analysis of 162 cases.

New insights into the biology of T-cell lymphomas

Advances in Targeted Drugs for Follicular Lymphoma

Recent Advances in the Treatment of Peripheral T-Cell Lymphoma

Updates in the Treatment of Peripheral T-Cell Lymphomas

The clinical features, treatment, and prognostic factors for peripheral T-cell lymphomas: A single-institution analysis of 240 Chinese patients

Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma

Genomics of Peripheral T-Cell Lymphoma and Its Implications for Personalized Medicine

Therapeutic challenges in peripheral T-cell lymphoma

Detangling the threads of Hairy Cell Leukemia, beyond the morphology and into the molecular